

2023 Winter Rheumatology Symposium Faculty Disclosures

The following types of relationships may be deemed relevant include:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria, includes speakers' bureau, symposia, and expert witness
7. Independent contractor
8. Ownership interest
9. Royalties
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other financial or material support

**All of the relevant financial relationships listed for the meeting faculty have been mitigated.*

Andersen, Paul, BA

Session: Livin' the Dream: An Aspen Writer Reflects on 50 Years in the Elk Range

Role: Speaker

Disclosure(s): No financial relationships with ineligible companies to disclose

Bermas, Bonnie, MD

Session: Reproductive Issues in Persons with Rheumatic Diseases

Role: Speaker

Session: Rheumatologic Immune Checkpoint Inhibitor Adverse Events

Role: Speaker

Disclosure(s): No financial relationships with ineligible companies to disclose

Block, Joel, MD

Session: Panel: Bone Diseases

Role: Moderator

Session: What's Happening in OA?

Role: Speaker

Session: WRS Committee

Role: Committee Chair

Disclosure(s): General Dynamics Information Technology: Independent Contractor (Terminated);

GlaxoSmithKlein(GSK): 2 (Terminated); Navitas Clinical Research: Independent Contractor (Ongoing); PK Med: 2 (Ongoing)

Dall'Era, Maria, MD

Sessions: Update on Therapy for Lupus and Panel: Inflammatory Arthritis

Role: Speaker

Disclosure(s): Amgen: 2 (Ongoing); AstraZeneca: 2 (Ongoing); Aurinia: 2 (Ongoing);

GlaxoSmithKlein(GSK): 2 (Ongoing)

Gravallese, Ellen, MD

Session: How Much Do You Know About Synovial Pathology?

Role: Speaker

Session: Inflammatory Pathways and Their Impact on Bone

Role: Speaker

Session: Panel: Bone Diseases

Role: Panelist

Disclosure(s): AMN Healthcare: 11 (Ongoing); Crisper Therapeutics: 11 (Ongoing); CVS Health Corp: 11 (Ongoing); Editas Medicine: 11 (Ongoing); Gingko Bioworks Holdings, Inc.: 11 (Ongoing); Intellia Therapeutics, Inc.: 11 (Ongoing)

James, Judith, MD, PhD

Session: Prediction and Prevention in Rheumatology

Role: Speaker

Session: Update on Sjögren's Disease

Role: Speaker

Disclosure(s): No financial relationships with ineligible companies to disclose

Makris, Una, MD, MSc

Session: Geriatric Rheumatology: Integrating Aging Principles into Practice

Role: Speaker

Session: Pragmatic Approaches to Interdisciplinary Management of Chronic Musculoskeletal Pain

Role: Speaker

Disclosure(s): No financial relationships with ineligible companies to disclose

Merkel, Peter, MD, MPH

Session: Update on Large-Vessel Vasculitis

Role: Speaker

Session: WRS Committee

Role: Committee Chair

Disclosure(s): AbbVie: 2 (Ongoing), 5 (Ongoing); AstraZeneca: 2 (Ongoing), 5 (Ongoing); Boeinger-

Ingelheim: 2 (Ongoing), 5 (Ongoing); Bristol-Myers Squibb: 2 (Ongoing), 5 (Ongoing); ChemoCentryx: 2 (Ongoing), 5 (Ongoing); CSL Behring: 2 (Ongoing); Dynacure: 2 (Ongoing); Eicos: 5 (Ongoing); Electra: 5 (Ongoing); EMDSerono: 2 (Terminated December 2021); Forbius: 2 (Terminated December 2021), 5 (Terminated December 2021); Genentech/Rochse: 2 (Terminated December 2021), 5 (Terminated December 2021); Genzyme/Sanofi: 2 (Terminated December 2021), 5 (Terminated December 2021); GlaxoSmithKline: 2 (Ongoing), 5 (Ongoing); Immagene: 2 (Ongoing); InflaRx: 2 (Ongoing), 5 (Ongoing); Janssen: 2 (Ongoing), Kiniksa: 2 (Terminated July 31, 2020); Kyverna: 2 (Ongoing), 11 (Ongoing); Magenta: 2 (Ongoing), Neutrolis: 2 (Ongoing), 5 (Ongoing); Novartis: 2 (Ongoing); Pfizer: 2 (Ongoing); Q32: 2 (Ongoing); Regeneron: 2 (Ongoing); Sparrow: 2 (Ongoing); Takeda: 2 (Ongoing), 5 (Ongoing); Up to Date: 9 (Ongoing).

Nigrovic, Peter, MD

Session: Autoinflammatory Diseases and Macrophage Activation Syndrome

Role: Speaker

Session: Update on Pediatric Rheumatology

Role: Speaker

Disclosure(s): American Academy of Pediatrics: Royalties (Ongoing); Bristol-Myers Squibb(BMS): 2 (Ongoing), 5 (Ongoing); CARRA: 4 (Terminated, June 30, 2022); Exo Therapeutics: 2 (Ongoing); Fresh Tracks Bio: 2 (Ongoing); Miach Ortho: 1(Terminated, December 2021); Novartis: 2 (Ongoing); Pfizer: 2 (Ongoing), 5 (Ongoing); Qiagen: 2 (Ongoing); Up to Date, Inc: 9 (Ongoing).

Ritchlin, Christopher, MD, MPH

Session: Panel: Inflammatory Arthritis

Role: Panelist

Disclosure(s): AbbVie: 2 (Ongoing), 6 (Ongoing); AbbVie/Abbott: 2 (Ongoing); Bristol-Myers Squibb: 2 (Ongoing); Eli Lilly: 2 (Ongoing); Gilead: 2 (Ongoing); Janssen: 2 (Ongoing); Novartis: 2 (Ongoing), Pfizer: 2 (Ongoing), 6 (Ongoing); Sanofi Pasteur Biologics LLC: 2 (Ongoing); UCB: 2 (Ongoing), 6 (Ongoing).

Ross, A. Silvia, MD

Session: Panel: Inflammatory Arthritis

Role: Moderator

Session: Points-on-Joints

Role: Moderator

Session: WRS Committee

Role: Committee Member

Disclosure(s): AbbVie/Abbott: 1(Ongoing), 6 (Ongoing); Amgen: 1(Ongoing), 6 (Ongoing); Bristol-Myers Squibb(BMS): 1(Terminated); Exagen: 1(Ongoing); Gilead: 1(Terminated); Janssen: 1(Ongoing); Lilly: 1(Ongoing), 6 (Ongoing); Novartis: 1(Ongoing); Pfizer: 1(Ongoing), 6(Ongoing); UCB: 1(Ongoing).

Saag, Kenneth, MD, MSc

Session: Osteoporosis 2023: Concepts and Controversies

Role: Speaker

Session: Panel: Bone Diseases

Role: Panelist

Session: Rethinking Treatment Approaches for Gout

Role: Speaker

Disclosure(s): Amgen: 5 (Ongoing); Horizon Pharmaceuticals: 5 (Ongoing); LG Chem: 5 (Ongoing); Radius: 5 (Ongoing); SOBI: 5 (Ongoing)

Schett, Georg, MD

Session: A Mechanistic Approach to the Treatment of PsA

Role: Speaker

Session: CAR-T Therapy for Rheumatic Diseases

Role: Speaker

Session: Panel: Inflammatory Arthritis

Role: Panelist

Disclosure(s): No financial relationships with ineligible companies to disclose

Weinblatt, Michael, MD

Session: Panel: Inflammatory Arthritis

Role: Panelist

Session: Therapeutics for Rheumatoid Arthritis

Role: Speaker

Disclosure(s): AbbVie/Abbott: 2 (Ongoing), 5 (Ongoing); Aclaris: 2 (Ongoing); Amgen: 2 (Terminated), 5 (Terminated); Aqtual: 2 (Ongoing), 5 (Ongoing); Bayer: 2 (Ongoing); Bristol-Myers Squibb(BMS): 2 (Ongoing), 5 (Ongoing); Canfite: 11 (Ongoing); Corevita: 2 (Ongoing); Eli Lilly 2 (Terminated), 5(Terminated); Eqrx: 2(Ongoing), Genosco: 2(Ongoing); Gilead: 2(Ongoing); GlaxoSmithKline (GSK): 2(Ongoing); Horizon: 2(Ongoing); InMedix: 11(Ongoing); Janssen: 2(Ongoing), 5(Ongoing); Johnson and Johnson: 2(Ongoing); Kyvrena: 2(Ongoing); Pfizer: 2(Ongoing); Rani: 2(Ongoing); Revolo: 2(Ongoing); Sanofi: 2(Ongoing); Scipher: 2(Ongoing); 11(Ongoing); Scirhom: 2(Ongoing); Set Point: 2(Ongoing); Tremeau: 2(Ongoing).

Winthrop, Kevin

Session: Between the Lines: The How, When, and What to Give of the ACR Vaccine Guidelines

Role: Speaker

Session: Post-Pandemic, Where Are We with COVID-19?

Role: Speaker

Disclosure(s): AbbVie/Abbott: 2 (Ongoing); AstraZeneca: 2 (Ongoing); Bristol-Myers Squibb(BMS): 2 (Ongoing), 5 (Ongoing); Eli Lilly: 2 (Ongoing); Galapagos: 2 (Ongoing); Gilead: 2 (Ongoing);

GlaxoSmithKlein(GSK): 2 (Ongoing); Novartis: 2 (Ongoing); Pfizer: 2(Ongoing), 5(Ongoing); Regeneron: 2(Ongoing); Roche: 2(Ongoing); Sanofi: 2(Ongoing); UCB: 2(Ongoing).